[Pulmonary function tests on the bronchospasmolytic effects of the beta-2-adrenergics: salbutamol, terbutaline and NAB 365 (double placebo experiment)].
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000403:Airway Resistance; D000420:Albuterol / Q000627:therapeutic use*; D000438:Alcohols / Q000627:therapeutic use; D000588:Amines / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D002712:Chlorides / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005100:Expectorants / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010627:Phenethylamines / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D013726:Terbutaline / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D000438:Alcohols; D000588:Amines; D002712:Chlorides; D005100:Expectorants; D010627:Phenethylamines; D013726:Terbutaline; D000420:Albuterol
Lungenfunktionsuntersuchungen zur bronchospasmolytischen Wirkung der beta-2-Adrenergika Salbutamol, Terbutalin und NAB 365 (Doppelblindversuch)